Cowen Starts Ocular Therapeutix (OCUL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St futures rise after tech rout; Mideast, tariffs in focus
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, but set for weekly rise on Middle East escalation
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- Matador Resources to acquire Paloma Permian for $1.275B
UPDATE: RBC Capital Starts Ocular Therapeutix (OCUL) at Outperform
August 19, 2014 6:46 AM EDT(Updated - August 19, 2014 6:59 AM EDT)
RBC Capital initiated coverage on Ocular Therapeutix (NASDAQ: OCUL) with an Outperform rating and a price target of $21.00.
Analyst Adnan Butt said, "We believe OCUL shares offer the potential for upside as the hydrogel, sustained technology platform... More
Oppenheimer Starts Ocular Therapeutix (OCUL) at Outperform
August 19, 2014 6:46 AM EDTOppenheimer initiated coverage on Ocular Therapeutix (NASDAQ: OCUL) with an Outperform rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Ocular Therapeutix click here. For more ratings news on Ocular Therapeutix click here.
Shares of Ocular Therapeutix closed at $14.33 yesterday.
... More